Spots Global Cancer Trial Database for Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Official Title: A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
Study ID: NCT05524935
Study Description
Brief Summary: This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Contact Details
Name: Nikhil I Khushalani, MD
Affiliation: Moffitt Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
